Liraglutide reduces plasma dihydroceramide levels in patients with type 2 diabetes

Liraglutide reduces plasma dihydroceramide levels in patients with type 2 diabetes

Abstract Background Emerging evidence supports that dihydroceramides (DhCer) and ceramides (Cer) contribute to the pathophysiology of insulin resistance and liver steatosis, and that their circulating concentrations are independently associated with cardiovascular outcomes. Circulating DhCer levels...

Full description

Bibliographic Details
Main Authors: Damien Denimal, Victoria Bergas, Jean-Paul Pais-de-Barros, Isabelle Simoneau, Laurent Demizieux, Patricia Passilly-Degrace, Benjamin Bouillet, Jean-Michel Petit, Alexia Rouland, Amandine Bataille, Laurence Duvillard, Bruno Vergès
Format: Article
Language:English
Published: BMC 2023-05-01
Series:Cardiovascular Diabetology
Subjects:
Type 2 diabetes
Liraglutide
Dihydroceramides
Ceramides
Online Access:https://doi.org/10.1186/s12933-023-01845-0

Internet

https://doi.org/10.1186/s12933-023-01845-0

Similar Items